Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease ...

Crinetics Pharmaceuticals reported positive topline results from Phase 2 studies of atumelnant for CAH and ACTH-dependent Cushing's syndrome.

Mineralys (MLYS) is transitioning to a pre-commercial stage, supported by robust Phase 3 data and a strengthened cash position of $593.6 million.

People who have chronic kidney disease (CKD) have a higher risk of heart disease and declining kidney function. Increased amounts of protein in the urine is a sign of kidney stress and is linked to ...

Purpose: The clinical benefits, adverse effects, pharmacokinetics, and recommendations for the appropriate use of the aldosterone antagonists spironolactone and eplerenone in patients with heart ...

Aldosterone escape and non-ACE pathways for angiotensin II production may explain, at least in part, the continued high mortality rates in heart failure patients despite the advances made in ...

Lorundrostat, a novel therapy which blocks the production of aldosterone from the adrenal glands, demonstrated clinically meaningful and sustained reductions in blood pressure in 1,083 patients with ...

Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of ...

Study Rundown: Diagnostic and therapeutic measures for the management of aldosterone-producing adrenal adenomas (APAs) are often invasive. Ultrasound-guided trans-gastric radiofrequency ablation ...

Please provide your email address to receive an email when new articles are posted on . Once-daily lorundrostat safely lowered 24-hour systolic BP compared with placebo in a phase 2 trial. A ...